Abstract is: Nita Patel (born 1965) is an Indian-American vaccinologist who leads vaccine development at Novavax. She oversaw the development of the Novavax COVID-19 vaccine.
| human | Q5 |
| P2671 | Google Knowledge Graph ID | /g/11j636zcl3 |
| P496 | ORCID iD | 0000-0003-4976-061X |
| P2038 | ResearchGate profile ID | Nita-Patel-3 |
| P69 | educated at | Sardar Patel University | Q7423720 |
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q94132496 | 2753. Induction of Broadly Cross-Reactive Immune Responses Against A(H3N2) Airuses: Results of a Phase 2 Trial of a Novel Recombinant Hemagglutinin Saponin-Adjuvanted Nanoparticle Seasonal Influenza Vaccine |
| Q40216493 | A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. |
| Q37335667 | A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults |
| Q34772752 | Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab |
| Q35687662 | Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein |
| Q42607464 | Correction for Hao et al., Infection and propagation of human rhinovirus C in human airway epithelial cells |
| Q40158643 | Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract |
| Q98709409 | First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine |
| Q100691272 | Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity |
| Q41040045 | Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus |
| Q33184928 | Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. |
| Q101220444 | Induction of Cross-reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine |
| Q89880122 | Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA |
| Q42262149 | Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo |
| Q59327787 | LB19. Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) in Infants |
| Q101163390 | NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge |
| Q45360940 | Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab |
| Q40069102 | Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes |
| Q98902656 | Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine |
| Q45161601 | Potential for palivizumab interference with commercially available antibody-antigen based respiratory syncytial virus diagnostic assays |
| Q58595178 | Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge |
| Q92644863 | Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection |
| Q92552696 | Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants |
| Q98467301 | Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate |
| Q100750028 | Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate |
| Q64233806 | Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein |
| Q40528265 | Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants |
| Q40419286 | Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization |
| Nita Patel | wikipedia | |
| Nita Patel | wikipedia | |
| Nita Patel | wikipedia | |
| ml | നിത പട്ടേൽ | wikipedia |
Search more.